Skip to main content
SpringerLink
Log in

Once-Daily Aminoglycoside Administration in Gram–Negative Sepsis

Economic and Practical Aspects

  • Review Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Summary

A fuller understanding of the pharmacodynamics of aminoglycoside antibiotics now exists compared with when they were introduced. Recent findings have shown that once-daily dosage regimens of aminoglycosides are as effective as bd or tid regimens in the Treatment of Gram-negative sepsis. However, radical changes in dosage frequency based on this knowledge are resisted by some physicians because of fears about the peak concentration Toxicity of aminoglycosides These fears have been shown to be misplaced. The delay in the translation of research findings into practice may be attributable to the sheer quantity of medical literature and the limited time that clinicians have available to read it.

Because healthcare resources are finite, physicians arc increasingly becoming aware of the need to use drug therapy in the most cost-effective way. An important component of amino glycoside therapy that may persuade clinicians to change their practice is the organised consideration of the various costs associated with different administration regimens. This review examines the source of those costs, and endorses once-daily dosage of aminoglycosides from both an economic and practical viewpoint.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Karlowsky JA, Zhanel GG, Davidson RJ. et al. Postantibiotic effect in Pseudomonas aeruginsa following single and multiple aminoglycoside exposures in vitro. J Antimicrob Chem other 1994; 33: 937–47

    CAS  Google Scholar 

  2. Daikos GL, Jackson GG, Lolans VT, et al. Adaptive resistance to aminoglycoside antibiotics from first–exposure down–regulation. J Infect Dis 1990; 162: 414–20

    Article  PubMed  CAS  Google Scholar 

  3. Daikos GL, Lolans VT, Jackson GG. First–exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use. Antimicrob Agents Chemother 1991; 35 (1): 117–23

    Article  PubMed  CAS  Google Scholar 

  4. Prins JM, Buller HR, Kuijper J, et al. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993 Feb 6; 341: 335–9

    Article  PubMed  CAS  Google Scholar 

  5. Noone P, Parsons TMC, Pattison JR, et al. Experience in monitoring gentamicin therapy during treatment of various gram–negative sepsis. BMJ 1974 Mar 16; 1: 477–81

    Article  PubMed  CAS  Google Scholar 

  6. Shrimpton SB, Milmoc M, Wilson APR, et al. Audit of prescription and assay of aminoglycosides in a UK teaching hospital. J Antimkrob Chemother 1993; 31: 599–606

    Article  CAS  Google Scholar 

  7. Li SC, Loannides-Demos W, Spicer WJ, et al. Prospective audit of aminoglycoside usage in a general hospital with assessments of clinical processes and adverse clinical outcomes. Med J Aust 1989: 151: 224–32

    PubMed  CAS  Google Scholar 

  8. Flint LM, Gott J, Short L, et al. Serum level monitoring of aminoglycoside antibiotics: limitations in intensive care unit related bacterial pneumonia. Arch Surg 1985; 120: 99–103

    Article  PubMed  CAS  Google Scholar 

  9. Summer WR, Michael JR, Lipsky JJ. Initial aminoglycoside levels in the critically ill. Crit Care Med 1983: 11 (12): 948–50

    Article  PubMed  CAS  Google Scholar 

  10. Zeitany KG, El Saghir NS, Santhosh-Kumar CHR. et al. Increased aminoglycoside dosage requirements in hematologic malignancy. Antimicrob Agents Chemother 1990; 34: 702–8

    Article  PubMed  CAS  Google Scholar 

  11. Claiborne Dunagan W, Woodward RS, Medoff G, et al. Antibiotic misuse in two clinical situations: positive blood culture and administration of aminoglycosides. Rev Infect Dis 1991: 13: 405–12

    Article  Google Scholar 

  12. Jackson GG, Riff LJ. Pseudomonas bacteremia: phatmacologic and other bases for failure of treatment with gentamicin. J Infect Dis 1971: 124 Suppl.124: 5185–91

    Google Scholar 

  13. Black RE, Lau WK, Weinstein RJ, et al. Ototoxicity of amikacin. Antimicrob Agents Chemother 1976; 9: 956–61

    Article  PubMed  CAS  Google Scholar 

  14. Mattie H, Craig WA, Pechere JC. Determinants of efficacy and toxicity of aminoglycosides. J Anti microb Chemother 1989; 24: 281–93

    Article  CAS  Google Scholar 

  15. Verpooten GA, Giuliano RA, Verbist L, et al. Once daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther 1989: 45 (1): 22–7

    Article  PubMed  CAS  Google Scholar 

  16. Hollender LF, Bahini J, De Manzini N, et al. A multicentric study of netilmicin once daily versus thrice daily in patients with appendicitis and other intra–abdominal infections. J Antimicrob Chemother 1989; 23: 773–83

    Article  PubMed  CAS  Google Scholar 

  17. Nordstrom L, Ringber H, Cronberg S, et al. Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity. J Antimicrob Chemother 1990: 25; 159–73

    Article  PubMed  CAS  Google Scholar 

  18. EORTC International Antimicrobial Therapy Cooperative Group. Single v. multiple daily doses of amikacin combined with ceftriaxone or ceftazidime for empirical therapy of fever in granulocytopenic cancer patients. Ann Intern Med 1993; 119: 584–93

    Google Scholar 

  19. De Vries PJ, Verkooyen RP, Leguit P, et al. Prospective raoom filed study of once daily versus thrice daily nctilmicitt regimens in patients with intra abdominal infections. Eur J Microbiol lnfect Dis 1990: 9: 161–8

    Article  Google Scholar 

  20. Sturm AW. Effects of a restrictive antibiotic policy on clinical efficacy of antibiotics and susceptibility patterns of organisms. Eur J Clin Microbiol Infect Dis 1990; 9: 381–9

    Article  PubMed  CAS  Google Scholar 

  21. Ter Braak EW, De Vries PJ, Bouter KP, et al. Once daily dosing regimen for aminoglycosides plus βlactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone. Am J Med 1990: 89: 58–66

    Article  PubMed  CAS  Google Scholar 

  22. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155: 93–9

    Article  PubMed  CAS  Google Scholar 

  23. Rozdzinski E, Kern WV, Reichle A, et al. Once daily versus, thrice daily dosing of netilmicin in combination with βlactam antibiotics as empirical therapy for febrile neutropenic patients. J Antimicrob Chemother 1993: 31: 585–98

    Article  PubMed  CAS  Google Scholar 

  24. Janknegt R. Aminoglycoside monitoring in the once–or twice daily era. Pharm World Sci 1993; 15 (4): 151–5

    Article  PubMed  CAS  Google Scholar 

  25. Peters DA. Implementation of research findings. Health Bull 1992; 50: 68–77

    CAS  Google Scholar 

  26. Evidence–Based Care Research Group. Evidence–based care: I. Setting priorities: how important is this problem? Can Med Assoc J 1994: 150 (8): 1249–53

    Google Scholar 

  27. Parker SE, Davey PG. Practicalities of once–daily aminoglycoside dosing. J Antimicrob Chemother 1993; 31: 4–8

    Article  PubMed  CAS  Google Scholar 

  28. Parker SE, Davey PG. Once daily aminoglycoside dosing. Lancet 1993: 341: 346–7

    Article  PubMed  CAS  Google Scholar 

  29. Davey P, Dodd T, Kerr S, et al. Audit of iv antibiotic administration. Pharm J 1990 Jun 30: 244: 793–6

    Google Scholar 

  30. Gyssens IC, van der Meer JWM, Lennards CA, et al. Cost of hospital antimicrobial chemotherapy. A method for global, cost calculation. Pharm Weekbl Sci 1991: 13: 248–53

    Article  PubMed  CAS  Google Scholar 

  31. Weinstein MC, Read JL, MacKay DN, et al. Cost effective choice of antimicrobial therapy for serious infections. J Gen Intern Med 1986 Nov/Dec: 1: 351–63

    Article  PubMed  CAS  Google Scholar 

  32. Plumridge RJ. Cost comparison of intravenous antibiotic administration. Med J Aust 1990: 153: 516–8

    PubMed  CAS  Google Scholar 

  33. Tanner DJ, Nazarian MQ. Cost containment associated with decreased parenteral amibiotic administration frequencies. Am J Med 1984; 77 Suppl. 4C: 104–10

    Google Scholar 

  34. Parker SE, Davey PC. Pharmacoeconomics of intravenous drug administration. Pharmaroeconomics 1992: 1: 103–15

    Article  CAS  Google Scholar 

  35. Birdwell SW, Meyer GE, Scheckelhoff DJ, et al. Survey of wastage from intravenous admixture in US hospitals. Pharmacoeconomics, 1993: 4: 271–7

    Article  PubMed  CAS  Google Scholar 

  36. Birdwell SW, Direct costs of intravenous delivery systems. Pharmacoeconomics 1993: 4 (1): 8–13

    Article  PubMed  CAS  Google Scholar 

  37. Vacani PF, Malek MMH, Davey PG, Cost of gentamicin assays carried out by microbiology laboratories. J Clin Pathol 1993; 46: 890–5

    Article  PubMed  CAS  Google Scholar 

  38. D’Angio RG, Stevenson JG, Lively BT, et al. Therapeutic drug monitoring: improved performance through educational intervention. Drug Monit 1990: 12: 173–81

    Article  Google Scholar 

  39. Zaske E, Cipolle RJ, Sirate RJ. Gentamicin dosage requirements: wide interpatient variations in 242 surgery patients with normal renal function. Surgery 1980; 87: 164–9

    PubMed  CAS  Google Scholar 

  40. Davey PG, Geddes AM, Gonda I, et al. Clinical experience with a method for adjusting gentamicin dose from measured drug clearance. J Antimicrob Chemother 1983; 12: 613–22

    Article  PubMed  CAS  Google Scholar 

  41. Nicolau D, Quintiliani R, Nightingale CH. Once daily gentamicin. Conn Med 1992: 56: 561–3

    PubMed  CAS  Google Scholar 

  42. De Broe M, Giuliano RA, Verpooten GA, Choice of drug and dosage regimen: two important risk factors for aminoglycoside nephrotoxicity. Am J Med 1986: 80 Suppl. 6B: 115–8

    Article  Google Scholar 

  43. Moore RD, Smith CR, Lipsky JJ, et al. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 1984: 100: 352–7

    PubMed  CAS  Google Scholar 

  44. Gatell JM, Ferran F, Araujo V, et al. Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides. Antimicrob Agent Chemother 1987; 31 (9): 1383–7

    Article  CAS  Google Scholar 

  45. Jackson GG, Arcieri G, Ototoxicity of gentamicin in man: a survey and controlled analysis of clinical experience in the United States. J Infect Dis 1971; 124 Suppl.: 5130–7

    Google Scholar 

  46. Matz GJ. Aminoglycoside Ototoxicity. Am J Otolaryngol 1986: 7: 117–9

    Article  PubMed  CAS  Google Scholar 

  47. Kahlmeter G, Dahlager JI, Aminoglycoside toxicity–a review of clinical studies published between 1975 and 1982. J Antimicrob Chemother 1984: 13 Suppl. A: 9–22

    Google Scholar 

  48. Eisenberg JM, Koffer H, Glick HA, et al. What is the cost of nephrotoxicity associated with aminoglycosides? Ann Intern Med 1987; 107: 900–9

    PubMed  CAS  Google Scholar 

  49. Ramsden RT, Ackrill P, Bobbing oscillopsia from gentamicin toxicity. Br J Audiol 1982: 16: 147–50

    Article  PubMed  CAS  Google Scholar 

  50. Berg K. The toxic effect of streptomycin on the vestibular and cochlear apparatus. Acta Otolaryngol 1951; 97 Suppl. 1; 1–47

    Google Scholar 

  51. Federspil P, Drug–induced sudden hearing loss and vestibular disturbances. Adv Otorhinolaryngol 1981; 27: 144–58

    PubMed  CAS  Google Scholar 

  52. Dayal VS, Smith EL, McCain WG, Cochlear and vestibular gentamicin toxicity. Arch Otolaryngol 1974: 100: 338–40

    Article  PubMed  CAS  Google Scholar 

  53. Duncan R, Melville ID, Severe rombergism due to gentamicin toxicity [letter]. BMJ 1987: 295: 1141

    Article  PubMed  CAS  Google Scholar 

  54. Brahams D. Dosage of gentamicin and monitoring of blood levels: an action fails. Lancet 1986: 1: 1395–6

    Article  PubMed  CAS  Google Scholar 

  55. Davey P, Hernanz C, Lynch W, et al. Human and non–financial costs of hospital–acquired infection. J Hosp Infect 1991: 18 Suppl. A: 79–84

    Article  Google Scholar 

  56. Brushwood DB. Government liable for failure to monitor a patients serum gentamicin in an army hospital. Am J Hosp Pharm 1992: 49: 1748–50

    PubMed  CAS  Google Scholar 

  57. Hencke D, £1/2m for boys made deaf by antibiotic. The Guardian 1984 Jan 13: Sect. Home News: 3 (col. 1)

  58. Zenz C. Occupational medicine. Chicago: Yearbook Medical Publishers, 1975

  59. Lightfoot L, Rogers L, Hundreds killed by doctors relying on outdated manuals. Sunday Times (Scottish Edition) 1995 Feb 2; Sect. 1; 1 (col. 4-7)

    Google Scholar 

  60. Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in gram–negative pneumonia. Am J Med 1984: 77: 657–62

    Article  PubMed  CAS  Google Scholar 

  61. Mosdell DM, Morris DM, Voltura A, et al. Antibiotic treatment for surgical peritonitis. Ann Surg 1991; 214 (5): 543–52

    Article  PubMed  CAS  Google Scholar 

  62. Gransden WR, Eykyn SJ, Phillips L, et al. Bacteraemia due to E. coli: a study of 861 episodes. Rev Infect Dis 1990: 12 (6): 1008–18

    Article  PubMed  CAS  Google Scholar 

  63. John JF. What price success? The continuing saga of the toxic: therapeutic ratio in the use of aminoglycoside antibiotics. J lnfect Dis 1988: 158: 1–6

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmacoeconomics Research Centre, Department of Clinical Pharmacology, Ninewells Hospital and Medical School, DO1 9SY, Dundee, Scotland

    Sharon E. Parker & Peter G. Davey

Authors
  1. Sharon E. Parker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter G. Davey
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Parker, S.E., Davey, P.G. Once-Daily Aminoglycoside Administration in Gram–Negative Sepsis. Pharmacoeconomics 7, 393–402 (1995). https://doi.org/10.2165/00019053-199507050-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199507050-00004

Keywords

Search

Navigation